COMMUNIQUÉS West-GlobeNewswire

Transactions in Connection with Share Buy-back Program
19/05/2025
Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital [...]
Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue
19/05/2025
HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) presents projected revenue for each market with exclusive distribution agreement. NIKA has previously reported an estimated [...]
Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors
19/05/2025
Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental Segments ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone [...]
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
19/05/2025
Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American [...]
Healthcare Consulting & Contracting (HC3) Founder and Senior Toxicologist Dr. J. David Krause Honored with AIHA’s 2024 Lila Albin Best IEQ Paper Award
19/05/2025
Tallahassee, Florida , May 19, 2025 (GLOBE NEWSWIRE) -- Healthcare Consulting & Contracting (HC3), a leader in environmental health and toxicology consulting, proudly announces that its Founder and Senior [...]
BeeCure Celebrates World Bee Day
19/05/2025
Poinciana, Fl , May 19, 2025 (GLOBE NEWSWIRE) -- As World Bee Day approaches on May 20th, BeeCure© proudly joins the global community in honoring the vital role bees play in sustaining our planet. This day not only [...]
The Developing Doctor Launches New Online Course to Empower Early-Career Physicians
19/05/2025
New Online Course Helps Early-Career Physicians Navigate the Critical Transition from Training to Thriving Iowa City, Iowa , May 19, 2025 (GLOBE NEWSWIRE) -- The Developing Doctor, a leader in physician coaching and [...]
PhotoniCare's OtoSight Demonstrates More Accurate Diagnosis and a 50 Percent Reduction in Antibiotic Usage for Pediatric Ear Infections in Large Randomized Controlled Trial
19/05/2025
DURHAM, N.C. and GRAND RAPIDS, Mich., May 19, 2025 (GLOBE NEWSWIRE) -- PhotoniCare Inc., a medical device company dedicated to delivering innovation to frontline care that demonstrably enhances patient outcomes, is [...]
NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy
19/05/2025
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological (Blood) [...]
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
19/05/2025
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)
19/05/2025
First XLRS study to demonstrate efficacy and positive safety data in a Phase I/II trial Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had [...]
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
19/05/2025
-- Enrollment Completed on Schedule; Topline Results Expected Q3 2025 -- -- Company to Present Poster Reviewing RE104 Phase 1 Results at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting on May [...]
Transactions under Novonesis’ share buyback program
19/05/2025
Please read the announcement in PDF Attachment 2025_25_Share_buyback_program
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
19/05/2025
SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 [...]
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
19/05/2025
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 [...]
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
19/05/2025
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy [...]
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
19/05/2025
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., [...]
STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases
19/05/2025
HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces [...]
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
19/05/2025
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence [...]

Pages